Funds with similar focus
|Ideaspring Capital||India, Bangalore|
|Great Spirit Ventures||United States, Mill Valley|
|Gryffindor Capital||United States, Chicago|
|BrownSavano Direct Capital Partners||United States, Baltimore|
|GADS Option Fund||United States, Irvine|
|For it||Japan, Chiyoda|
|Jinfeng Investment||China, Shanghai|
|Galvanize||United States, Denver|
|Starship Ventures||United States, San Francisco|
|$100M||16 Jun 2021||United States, " United States"}|
|$336M||19 Apr 2021||United States, " United States"}|
|$188M||14 Jan 2021||Netherlands, " The Netherlands"}|
|$80M||10 Nov 2020||United States, " United States"}|
– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.